His primary areas of study are Multiple myeloma, Internal medicine, Surgery, Oncology and Bortezomib. His studies deal with areas such as Chemotherapy, Dexamethasone and Transplantation as well as Multiple myeloma. His Transplantation research focuses on subjects like Clinical endpoint, which are linked to Hazard ratio.
His studies examine the connections between Internal medicine and genetics, as well as such issues in Gastroenterology, with regards to Beta-2 microglobulin. While the research belongs to areas of Surgery, Thierry Facon spends his time largely on the problem of Urology, intersecting his research to questions surrounding Induction chemotherapy. His biological study spans a wide range of topics, including Clinical trial, Pathology, Immunology, Very Good Partial Response and Survival analysis.
His primary areas of investigation include Multiple myeloma, Internal medicine, Oncology, Surgery and Lenalidomide. His Multiple myeloma study incorporates themes from Newly diagnosed, Transplantation and Dexamethasone. His research in Internal medicine intersects with topics in Gastroenterology and Immunology.
His Oncology study also includes
His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Dexamethasone and Lenalidomide. Thierry Facon has included themes like Newly diagnosed, Adverse effect and Transplantation in his Multiple myeloma study. His work in Internal medicine is not limited to one particular discipline; it also encompasses Gastroenterology.
In his study, Clinical trial is strongly linked to Randomized controlled trial, which falls under the umbrella field of Dexamethasone. His Lenalidomide research incorporates elements of Thalidomide, Survival rate, Surgery, Phases of clinical research and Clinical endpoint. His Bortezomib research includes themes of Proteasome inhibitor and Autologous stem-cell transplantation.
His main research concerns Multiple myeloma, Internal medicine, Lenalidomide, Oncology and Bortezomib. His Multiple myeloma study incorporates themes from Interim analysis, Clinical trial, MEDLINE, Adverse effect and Transplantation. His Internal medicine study often links to related topics such as Gastroenterology.
Thierry Facon interconnects Survival rate, Clinical endpoint, Thalidomide and Pembrolizumab in the investigation of issues within Lenalidomide. The concepts of his Thalidomide study are interwoven with issues in Autologous stem-cell transplantation and Melphalan. His studies deal with areas such as Prospective cohort study and Surgery as well as Bortezomib.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Michel Attal;Jean-Luc Harousseau;Anne-Marie Stoppa;Jean-Jacques Sotto.
The New England Journal of Medicine (1996)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince.
The New England Journal of Medicine (2007)
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Michel Attal;Jean-Luc Harousseau;Thierry Facon;François Guilhot.
The New England Journal of Medicine (2003)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Thierry Facon;Jean Yves Mary;Cyrille Hulin;Lotfi Benboubker.
The Lancet (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel.
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal;Jean-Luc Harousseau;Serge Leyvraz;Chantal Doyen.
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton.
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
Catherine Roche-Lestienne;Valerie Soenen-Cornu;Nathalie Grardel-Duflos;Jean-Luc Laı̈.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua.
Lancet Oncology (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: